STOCKHOLM, Sweden--(BUSINESS WIRE)--The biopharma company Biovitrum (STO:BVT), listed on the Stockholm Stock Exchange since September 15, 2006, has entered an agreement with the Uppsala-based biotech company Synphora regarding a new drug candidate (JB991) for the treatment of the skin disease psoriasis and other conditions.
